PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback